Skip to main content
. Author manuscript; available in PMC: 2016 Aug 29.
Published in final edited form as: Oncogene. 2013 Sep 9;33(27):3519–3527. doi: 10.1038/onc.2013.338

Figure 1. Burkitt’s Lymphoma Myc mutants enhance Myc-induced cell transformation independently of loss of T58 phosphorylation and increased expression.

Figure 1

A) Rat1a fibroblasts were engineered to express MycWT, the indicated Burkitt’s Lymphoma (BL) Myc mutants or vector control. Cell extracts were analyzed by Western blot using anti-Myc or anti-Tubulin antibodies. B) MycWT and the BL-associated Myc mutants were transiently expressed in 293 cells. Cell extracts were analyzed by parallel western blots using anti-phospho-Myc (p58/p62) or anti-Myc (phospho-independent). C) The half-life of MycWT and BL-associated mutants was determined by engineering myc−/− fibroblast to express the indicated proteins, and cells were treated with 50 μg/mL cycloheximide for the up to 120 minutes. Cell extracts were analyzed by western blot using anti-Myc antibodies D) Log phase Rat1a fibroblasts expressing MycWT or BL-associated Myc mutants were used in a soft agar transformation assay. The chart depicts the diameter of colonies from each cell line after 1 week of growth. Error bars indicate the standard deviation (SD) for three biological replicates using two independently engineered cell line. Significance was determined using student’s t-test; *p≤0.05.